Small Cap Biotechs

For Biotech and Pharmaceutical Companies

Looking for Financing, PR or Investor Relations Services?

We facilitate introductions to leading hedge funds who share your company's best interests and may be interested in investing in you. We also bump shoulders with some of the premier Investor Relations & PR firms in the United States. We've a track record of success which supports these relationships, and a network that feeds our success. If you have a company in need of greater visibility or capital investment, we'd like to hear from you.

Biotech News and Updates

Sientra (NASDAQ: SIEN) : DD and More

December 13, 2015

Comments Off

A few excerpts:

PennyStockHaven:

From Sientra’s (SIEN) 8-K filing from October 30th, 2015:
We continue to be well funded with a cash and cash equivalents balance of $148.9 million as of September 30, 2015. Earlier

SANUWAVE (SNWV): U.S. Patent to Sterilize Blood Using SNWV’s Shock Wave Technology

April 11, 2013

Comments Off

SANUWAVE Health, Inc. (OTCBB:SNWV) has received a patent issued by the U.S. Patent and Trademark Office entitled “Method and Devices for Cleaning and Sterilization with Shock Waves.” The claims of the patent (patent number 8,343,420) relate to a new method that sterilizes

BioCryst Pharmaceuticals (BCRX): Update Regarding Peramivir

April 1, 2013

Comments Off

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and inflammatory diseases.

BioCryst announced that it received a preliminary comment letter from the FDA that

Cell Therapeutics, Inc.(CTIC): $15MM Loan Financing Agreement

March 28, 2013

Comments Off

Cell Therapeutics, Inc. (CTIC) announced that it has entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. for a senior secured term loan of up to $15 million. The first

AntriaBio (ANTB): An Opportunity

March 17, 2013

Comments Off

Novo Nordisk – the world ‘s largest insulin producer – and major diabetes drug manufacturers – could see BILLIONS in recurring revenue dry up as a small, California-based biotech company advances a technology that promises to change diabetes treatment.

Over $100,000,000 has been invested in developing this super-drug that threatens to make products like Sanofi’ s $6 BILLION-A-YEAR basal insulin – ‘Lantus’ – OBSOLETE.

The Company that ‘s making executives in the world’ s largest pharmaceutical firms sweat is Menlo Park, California-based ANTRIABIO, INC. (ANTB)

Here ‘s why large pharma is worried about ANTRIABIO’ s technology:

Basal

Oncolytics Biotech (ONCY): Positive REOLSYIN Clinical Trial Data from Phase 2 Study

February 8, 2013

Comments Off

Oncolytics Biotech Inc. (NASDAQ: ONCY) is focused on the development of oncolytic viruses for use as cancer therapeutics. The Company’s lead product, REOLYSIN®, a proprietary formulation of the human reovirus, is currently in late stage

Although PNH flopped, Achillion Shows Promising Early C3G Results
Tue, Dec 18
Yesterday after market, Achillion (ACHN) released data and a strategic update, including interim data · more »
Affimed Outlines Development Pathway for AFM13
Fri, Dec 14
During their RD Day call last week, Affimed shared details on the clinical development plan for AFM13 · more »
Did Bellus Raise $35M As A Result Of Overwhelming Institutional Interest?
Tue, Dec 11
Bellus announced a $35M CDN raise this morning at $0.95 CDN. That is roughly equivalent to $0.71 USD. · more »
Oncosec’s Tone Seems to Have Changed in TNBC
Tue, Dec 11
Oncosec finally announced an update from their early stage triple negative breast cancer trial. This · more »
A Look at Bellus’ Upcoming 2019 Catalysts
Thu, Nov 29
There is a misconception that Bellus is lacking catalysts following their strong Phase 1 data released · more »
It’s Worthwhile Watching Affimed & Achillion Ahead of December Data
Wed, Nov 28
We are looking forward to December catalysts and watching two companies with near term readouts that we · more »
Market Misinterprets Bellus’ Promising Phase 1 Data
Tue, Nov 20
Bellus had a call this morning (listen here) to discuss their Phase 1 data, released yesterday after · more »
Placebo Overshadows Amarin’s REDUCE-IT Data. Should It Actually Matter?
Mon, Nov 12
Amarin released detailed REDUCE-IT data this past Saturday and results were mixed. Although the · more »
What’s Next for Oncosec Following Premature Melanoma Data
Tue, Nov 6
Oncosec (ONCS) reported data from PICES combination trial with Keytruda this morning and came below · more »

Recent Updates

For Biotech and Pharmaceutical Companies

Looking for Financing, PR or Investor Relations Services?

Biotech News and Updates

Sientra (NASDAQ: SIEN) : DD and More

SANUWAVE (SNWV): U.S. Patent to Sterilize Blood Using SNWV’s Shock Wave Technology

BioCryst Pharmaceuticals (BCRX): Update Regarding Peramivir

Cell Therapeutics, Inc.(CTIC): $15MM Loan Financing Agreement

AntriaBio (ANTB): An Opportunity

Oncolytics Biotech (ONCY): Positive REOLSYIN Clinical Trial Data from Phase 2 Study

Biotech Stocks Reviews